Advertisement

Expanding the Molecular Landscape of Cutaneous T-Cell Lymphoma

Published:September 28, 2022DOI:https://doi.org/10.1016/j.yamp.2022.05.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Molecular Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Willemze R.
        • Cerroni L.
        • Kempf W.
        • et al.
        The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.
        Blood. 2019; 133 ([published correction appears in Blood. 2019 Sep 26;134(13):1112]): 1703-1714
        • Torres-Cabala C.A.
        Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together.
        Mod Pathol. 2020; 33: 83-95
        • Willemze R.
        • Jaffe E.S.
        • Burg G.
        • et al.
        WHO-EORTC classification for cutaneous lymphomas.
        Blood. 2005; 105: 3768-3785
        • Agar N.S.
        • Wedgeworth E.
        • Crichton S.
        • et al.
        Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
        J Clin Oncol. 2010; 28: 4730-4739
        • Whittaker S.J.
        • Cerroni L.
        • Willemze R.
        • et al.
        Sézary syndrome.
        in: Swerdlow S.H. Campo E. Harris N.L. Classification of tumours of haematopoietic and lymphoid tissues, revised. 4th edition. IARC Press, Lyon (France)2017: 90
        • Ponti R.
        • Quaglino P.
        • Novelli M.
        • et al.
        T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
        Br J Dermatol. 2005; 153: 565-573
        • Comfere N.
        • Sundram U.
        • Hurley M.Y.
        • et al.
        Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T-cell and B-cell lymphoproliferative disorders.
        J Cutan Pathol. 2018; 45: 39-47
        • Jawed S.I.
        • Myskowski P.L.
        • Horwitz S.
        • et al.
        Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
        J Am Acad Dermatol. 2014; 70: e201-e216
        • Xu C.
        • Wan C.
        • Wang L.
        • et al.
        Diagnostic significance of TCR gene clonal rearrangement analysis in early mycosis fungoides.
        Chin J Cancer. 2011; 30: 264-272
        • Hodges E.
        • Krishna M.T.
        • Pickard C.
        • et al.
        Diagnostic role of tests for T cell receptor (TCR) genes.
        J Clin Pathol. 2003; 56: 1-11
        • Hsiao P.F.
        • Hsiao C.H.
        • Lin Y.C.
        • et al.
        Histopathologic-molecular correlation in early mycosis fungoides using T-cell receptor gamma gene rearrangement by polymerase chain reaction with laser capture microdissection.
        J Formos Med Assoc. 2007; 106: 265-272
        • Ponti R.
        • Fierro M.T.
        • Quaglino P.
        • et al.
        TCRgamma-chain gene rearrangement by PCR-based GeneScan: diagnostic accuracy improvement and clonal heterogeneity analysis in multiple cutaneous T-cell lymphoma samples.
        J Invest Dermatol. 2008; 128: 1030-1038
        • Walia R.
        • Yeung C.C.S.
        An update on molecular biology of cutaneous T cell lymphoma.
        Front Oncol. 2020; 9: 1558
        • Sufficool K.E.
        • Lockwood C.M.
        • Abel H.J.
        • et al.
        T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides.
        J Am Acad Dermatol. 2015; 73: 228-236.e2
        • Olsen E.
        • Vonderheid E.
        • Pimpinelli N.
        • et al.
        Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
        Blood. 2007; 110: 1713-1722
        • Weng W.K.
        • Armstrong R.
        • Arai S.
        • et al.
        Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
        Sci Transl Med. 2013; 5: 214ra171
        • Hurabielle C.
        • Ingen-Housz-Oro S.
        • Ortonne N.
        • et al.
        Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group.
        Br J Dermatol. 2015; 173: 1015-1023
        • Massone C.
        • Crisman G.
        • Kerl H.
        • et al.
        The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality.
        Br J Dermatol. 2008; 159: 881-886
        • de Masson A.
        • O'Malley J.T.
        • Elco C.P.
        • et al.
        High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.
        Sci Transl Med. 2018; 10: eaar5894
        • Choi J.
        • Goh G.
        • Walradt T.
        • et al.
        Genomic landscape of cutaneous T cell lymphoma.
        Nat Genet. 2015; 47: 1011-1019
        • Vermeer M.H.
        • van Doorn R.
        • Dijkman R.
        • et al.
        Novel and highly recurrent chromosomal alterations in Sézary syndrome.
        Cancer Res. 2008; 68: 2689-2698
        • Mao X.
        • Lillington D.
        • Scarisbrick J.J.
        • et al.
        Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides.
        Br J Dermatol. 2002; 147: 464-475
        • Woollard W.J.
        • Pullabhatla V.
        • Lorenc A.
        • et al.
        Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
        Blood. 2016; 127: 3387-3397
        • Wang L.
        • Ni X.
        • Covington K.R.
        • et al.
        Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
        Nat Genet. 2015; 47: 1426-1434
        • Sekulic A.
        • Liang W.S.
        • Tembe W.
        • et al.
        Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.
        Mol Genet Genomic Med. 2015; 3: 130-136
        • Prasad A.
        • Rabionet R.
        • Espinet B.
        • et al.
        Identification of gene mutations and fusion genes in patients with Sézary syndrome.
        J Invest Dermatol. 2016; 136: 1490-1499
        • Vaqué J.P.
        • Gómez-López G.
        • Monsálvez V.
        • et al.
        PLCG1 mutations in cutaneous T-cell lymphomas.
        Blood. 2014; 123: 2034-2043
        • Ungewickell A.
        • Bhaduri A.
        • Rios E.
        • et al.
        Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
        Nat Genet. 2015; 47: 1056-1060
        • Lee C.S.
        • Ungewickell A.
        • Bhaduri A.
        • et al.
        Transcriptome sequencing in Sézary syndrome identifies Sézary cell and mycosis fungoides-associated lncRNAs and novel transcripts.
        Blood. 2012; 120: 3288-3297
        • da Silva Almeida A.C.
        • Abate F.
        • Khiabanian H.
        • et al.
        The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
        Nat Genet. 2015; 47: 1465-1470
        • McGirt L.Y.
        • Jia P.
        • Baerenwald D.A.
        • et al.
        Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.
        Blood. 2015; 126: 508-519
        • Kiel M.J.
        • Sahasrabuddhe A.A.
        • Rolland D.C.
        • et al.
        Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.
        Nat Commun. 2015; 6: 8470
        • Izykowska K.
        • Przybylski G.K.
        • Gand C.
        • et al.
        Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
        Oncotarget. 2017; 8: 39627-39639
        • Damsky W.E.
        • Choi J.
        Genetics of cutaneous T cell lymphoma: from bench to bedside.
        Curr Treat Options Oncol. 2016; 17: 33
        • Larocca C.
        • Kupper T.
        Mycosis fungoides and Sézary syndrome: an update.
        in: LeBoeuf N.R. Larocca C. Cutaneous malignancy. Elsevier, Philadelphia2019: p113
        • Wooler G.
        • Melchior L.
        • Ralfkiaer E.
        • et al.
        TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides.
        Front Med (Lausanne). 2016; 3: 51
        • Stolearenco V.
        • Namini M.R.J.
        • Hasselager S.S.
        • et al.
        Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma.
        Front Cell Dev Biol. 2020; 8: 851
        • Zhang Y.
        • Wang Y.
        • Yu R.
        • et al.
        Molecular markers of early-stage mycosis fungoides.
        J Invest Dermatol. 2012; 132: 1698-1706
        • Huang Y.
        • Litvinov I.V.
        • Wang Y.
        • et al.
        Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis.
        Oncotarget. 2014; 5: 4418-4425
        • Yu X.
        • Li Z.
        TOX gene: a novel target for human cancer gene therapy.
        Am J Cancer Res. 2015; 5: 3516-3524
        • Bagot M.
        New targeted treatments for cutaneous T-cell lymphomas.
        Indian J Dermatol. 2017; 62: 142-145
        • Izban K.F.
        • Ergin M.
        • Qin J.Z.
        • et al.
        Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis.
        Hum Pathol. 2000; 31: 1482-1490
        • Pérez C.
        • González-Rincón J.
        • Onaindia A.
        • et al.
        Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.
        Haematologica. 2015; 100: e450-e453
        • Pérez C.
        • Mondéjar R.
        • García-Díaz N.
        • et al.
        Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
        Br J Dermatol. 2020; 182: 147-155
        • Litvinov I.V.
        • Netchiporouk E.
        • Cordeiro B.
        • et al.
        The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL).
        Clin Cancer Res. 2015; 21: 2820-2829
        • Nebozhyn M.
        • Loboda A.
        • Kari L.
        • et al.
        Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy.
        Blood. 2006; 107: 3189-3196
        • Michel L.
        • Jean-Louis F.
        • Begue E.
        • et al.
        Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
        Blood. 2013; 121: 1477-1478
        • Ralfkiaer U.
        • Hagedorn P.H.
        • Bangsgaard N.
        • et al.
        Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL).
        Blood. 2011; 118: 5891-5900
        • Lindahl L.M.
        • Besenbacher S.
        • Rittig A.H.
        • et al.
        Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study.
        Blood. 2018; 131: 759-770
        • Bekkenk M.W.
        • Geelen F.A.
        • van Voorst Vader P.C.
        • et al.
        Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.
        Blood. 2000; 95: 3653-3661
        • Willemze R.
        • Paulli M.
        • Kadin M.E.
        Primary cutaneous CD30-positive lymphoproliferative disorders.
        in: Swerdlow S.H. Campo E. Harris N.L. Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. IARC Press, Lyon (France)2017: p395
        • Sun J.
        • Yi S.
        • Qiu L.
        • et al.
        SATB1 defines a subtype of cutaneous CD30+ lymphoproliferative disorders associated with a T-helper 17 cytokine profile.
        J Invest Dermatol. 2018; 138: 1795-1804
        • Karai L.J.
        • Kadin M.E.
        • Hsi E.D.
        • et al.
        Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis.
        Am J Surg Pathol. 2013; 37: 173-181
        • Wada D.A.
        • Law M.E.
        • Hsi E.D.
        • et al.
        Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
        Mod Pathol. 2011; 24: 596-605
        • Laharanne E.
        • Oumouhou N.
        • Bonnet F.
        • et al.
        Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.
        J Invest Dermatol. 2010; 130: 1707-1718
        • van Kester M.S.
        • Tensen C.P.
        • Vermeer M.H.
        • et al.
        Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.
        J Invest Dermatol. 2010; 130: 563-575
        • Velusamy T.
        • Kiel M.J.
        • Sahasrabuddhe A.A.
        • et al.
        A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
        Blood. 2014; 124: 3768-3771
        • Oschlies I.
        • Lisfeld J.
        • Lamant L.
        • et al.
        ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.
        Haematologica. 2013; 98: 50-56
        • Wehkamp U.
        • Oschlies I.
        • Nagel I.
        • et al.
        ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.
        J Cutan Pathol. 2015; 42: 870-877
        • Vasmatzis G.
        • Johnson S.H.
        • Knudson R.A.
        • et al.
        Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
        Blood. 2012; 120: 2280-2289
        • Chavan R.N.
        • Bridges A.G.
        • Knudson R.A.
        • et al.
        Somatic rearrangement of the TP63 gene preceding development of mycosis fungoides with aggressive clinical course.
        Blood Cancer J. 2014; 4: e253
        • Bekkenk M.W.
        • Vermeer M.H.
        • Jansen P.M.
        • et al.
        Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients.
        Blood. 2009; 102: 2213-2219
        • Gaulard P.
        • Berti E.
        • Willemze R.
        • et al.
        Primary cutaneous peripheral T-cell lymphoma, rare subtypes.
        in: Swerdlow S.H. Campo E. Harris N.L. Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. IARC Press, Lyon (France)2017: p397-p402
        • Rodríguez Pinilla S.M.
        • Roncador G.
        • Rodríguez-Peralto J.L.
        • et al.
        Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers.
        Am J Surg Pathol. 2009; 33: 81-90
        • Alberti-Violetti S.
        • Torres-Cabala C.A.
        • Talpur R.
        • et al.
        Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma.
        J Cutan Pathol. 2016; 43: 1121-1130
        • Kumar S.
        • Krenacs L.
        • Medeiros J.
        • et al.
        Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes.
        Hum Pathol. 1998; 29: 397-403
        • Gonzalez C.L.
        • Medeiros L.J.
        • Braziel R.M.
        • et al.
        T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome.
        Am J Surg Pathol. 1991; 15: 17-27
        • Oschlies I.
        • Simonitsch-Klupp I.
        • Maldyk J.
        • et al.
        Subcutaneous panniculitis-like T-cell lymphoma in children: a detailed clinicopathological description of 11 multifocal cases with a high frequency of haemophagocytic syndrome.
        Br J Dermatol. 2015; 172: 793-797
        • Guitart J.
        Subcutaneous lymphoma and related conditions.
        Dermatol Ther. 2010; 23: 350-355
        • Gayden T.
        • Sepulveda F.E.
        • Khuong-Quang D.A.
        • et al.
        Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.
        Nat Genet. 2018; 50: 1650-1657
        • Willemze R.
        • Jansen P.M.
        • Cerroni L.
        • et al.
        Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.
        Blood. 2008; 111: 838-845
        • Guitart J.
        • Weisenburger D.D.
        • Subtil A.
        • et al.
        Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas.
        Am J Surg Pathol. 2012; 36: 1656-1665
        • Daniels J.
        • Doukas P.G.
        • Escala M.E.M.
        • et al.
        Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas.
        Nat Commun. 2020; 11: 1806
        • Merrill E.D.
        • Agbay R.
        • Miranda R.N.
        • et al.
        Primary cutaneous T-cell lymphomas showing gamma-delta (γδ) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous γδ T-cell lymphomas.
        Am J Surg Pathol. 2017; 41: 204-215
        • Robson A.
        • Assaf C.
        • Bagot M.
        • et al.
        Aggressive epidermotropic cutaneous CD30(+) lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop.
        Histopathology. 2015; 67: 425-441
        • Lee K.
        • Evans M.G.
        • Yang L.
        • et al.
        Primary cutaneous cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
        Blood. 2021; 138: 2435-2440
        • Kim Y.H.
        • Bagot M.
        • Pinter-Brown L.
        • et al.
        Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
        Lancet Oncol. 2018; 19: 1192-1204
        • Prince H.M.
        • Kim Y.H.
        • Horwitz S.M.
        • et al.
        Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
        Lancet. 2017; 390: 555-566
        • Bastidas Torres A.N.
        • Cats D.
        • Mei H.
        • et al.
        Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides.
        Genes Chromosomes Cancer. 2018; 57: 653-664
        • Horwitz S.M.
        • Koch R.
        • Porcu P.
        • et al.
        Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
        Blood. 2018; 131: 888-898
        • Khodadoust M.S.
        • Rook A.H.
        • Porcu P.
        • et al.
        Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study.
        J Clin Oncol. 2020; 38: 20-28